Abstract:Recently, Leydig cell (LCs) transplantation has a promising potential to treat male hypogonadism. However, the scarcity of seed cells is the actual barrier impeding the application of LCs transplantation. Utilizing the cutting-edge CRISPR/dCas9VP64 technology, human foreskin fibroblasts (HFFs) were transdifferentiated into Leydig-like cells(iLCs) in previous study, but the efficiency of transdifferentiation is not very satisfactory. Therefore, this study was conducted to further optimize the CRISPR/dCas9 system for obtaining sufficient iLCs. First, the stable CYP11A1-Promoter-GFP-HFFs cell line was established by infecting HFFs with CYP11A1-Promoter-GFP lentiviral vectors, and then co-infected with dCas9p300 and the combination of sgRNAs targeted to NR5A1, GATA4 and DMRT1. Next, this study adopted quantitative reverse transcription polymerase chain reaction (qRT-PCR), Western blot, and immunofluorescence to determine the efficiency of transdifferentiation, the generation of testosterone, the expression levels of steroidogenic biomarkers. Moreover, we utilized chromatin immuno-precipitation (ChIP) followed by quantitative polymerase chain reaction (ChIP-qPCR) to measure the levels of acetylation of targeted H3K27. The results revealed that advanced dCas9p300 facilitated generation of iLCs. Moreover, the dCas9p300-mediated iLCs significantly expressed the steroidogenic biomarkers and produced more testosterone with or without LH treatment than the dCas9VP64-mediated. Additionally, preferred enrichment in H3K27ac at the promoters was detected only with dCas9p300 treatment. The data provided here imply that the improved version of dCas9 can aid in the harvesting of iLCs, and will provide sufficient seed cells for cell transplantation treatment of androgen deficiency in the future.

Conversion of Human Fibroblasts into Functional Leydig-like Cells by Small Molecules and a Single Factor.

Conversion of Fibroblast into Functional Leydig-like Cell Using Defined Small Molecules

Direct Conversion of Human Fibroblasts into Functional Leydig-like Cells by SF-1, GATA4 and NGFI-B.

Direct Reprogramming of Mouse Fibroblasts Toward Leydig-like Cells by Defined Factors

High-fidelity Reprogramming into Leydig-like Cells by CRISPR Activation and Paracrine Factors.

CRISPR/dCas9-mediated Activation of Multiple Endogenous Target Genes Directly Reprograms Human Foreskin Fibroblasts into Leydig-like Cells

Generation of Leydig-like Cells: Approaches, Characterization, and Challenges

Leydig-like Cells Derived from Reprogrammed Human Foreskin Fibroblasts by CRISPR/dCas9 Increase the Level of Serum Testosterone in Castrated Male Rats

Differentiation of human induced pluripotent stem cells into Leydig-like cells with molecular compounds

Epigenome editing based on CRISPR/dCas9p300 facilitates transdifferentiation of human fibroblasts into Leydig-like cells

Directed Mouse Embryonic Stem Cells into Leydig-Like Cells Rescue Testosterone-Deficient Male Rats in Vivo.

Pharmacological Reprogramming of Fibroblasts into Neural Stem Cells by Signaling-Directed Transcriptional Activation

Converting Skin Fibroblasts into Hepatic-Like Cells by Transient Programming

Small-Molecule-Driven Direct Reprogramming of Fibroblasts into Functional Sertoli-Like Cells as a Model for Male Reproductive Toxicology

Small Molecules Enable Cardiac Reprogramming of Mouse Fibroblasts with a Single Factor, Oct4.

Directing differentiation of human induced pluripotent stem cells toward androgen-producing Leydig cells rather than adrenal cells

Reprogramming of Human Fibroblasts into Multipotent Cells with A Single Ecm Proteoglycan, Fibromodulin

Small Molecules Facilitate the Reprogramming of Mouse Fibroblasts into Pancreatic Lineages

Reprogramming Fibroblasts Toward Cardiomyocytes, Neural Stem Cells and Hepatocytes by Cell Activation and Signaling-Directed Lineage Conversion

An autofluorescence-based isolation of Leydig cells for testosterone deficiency treatment

Small Molecules Facilitate Single Factor-Mediated Hepatic Reprogramming